The combined treatment with 14 and pictilisib, a small-molecule class I PI3K inhibitor, was more effective than treatment with a combination of the EGFR inhibitor lapatinib and trastuzumab in parental SW48 and LIM1215 and in HER2-amplified human colon cancer cell lines. This evidence concerns the gene ERBB2 and colonic neoplasm.